All Trials

A PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolls treatment-naïve adults with locally advanced or metastatic HER2-negative, PD-L1–positive gastric, gastroesophageal junction, or esophageal adenocarcinoma and ECOG 0–1. Patients receive PF-08634404/SSGJ-707, an investigational bispecific antibody targeting PD-1 and VEGF, plus chemotherapy, with phase 3 comparison against nivolumab plus chemotherapy.

ClinicalTrials.gov ID: NCT07392892

A Phase 2 Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma - SPARCC

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study for treatment-naïve adults with measurable unresectable advanced or metastatic RCC with clear cell component, including sarcomatoid features, or defined translocation RCC, ECOG 0–2. Patients receive sasanlimab, an anti–PD-1 antibody, plus palbociclib, an oral CDK4/6 inhibitor, and axitinib, an oral VEGFR TKI.

ClinicalTrials.gov ID: NCT07123090

A Randomized Phase II Trial of Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Oligo-Metastatic Clear Cell Renal Cell Carcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with oligometastatic clear cell renal cell carcinoma with 1–5 RECIST-measurable lesions amenable to definitive SBRT, including the primary tumor if present, receive SBRT to all disease sites and are then randomized to cemiplimab, an anti–PD-1 antibody, with or without fianlimab, an anti–LAG-3 antibody. Treatment is given every 3 weeks for up to 1 year to test whether dual checkpoint blockade improves 1-year progression-free survival after SBRT.

ClinicalTrials.gov ID: NCT07223541

A Phase II Trial of Telisotuzumab Vedotin With Osimertinib for EGFR Mutated NSCLC With c-MET Overexpression That is Progressing on Osimertinib

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study for adults with incurable EGFR-mutated, predominantly adenocarcinoma NSCLC with c-MET overexpression after progression on osimertinib, ECOG 0–1, measurable disease, and no active/symptomatic CNS disease or significant ILD/pneumonitis. Patients continue osimertinib 80 mg daily with telisotuzumab vedotin, a c-MET–directed antibody-drug conjugate delivering the microtubule inhibitor MMAE.

ClinicalTrials.gov ID: NCT07323641

ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥ 50%.

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Randomized first-line study for adults with unresectable stage IIIB/IIIC or stage IV squamous or nonsquamous NSCLC, PD-L1 ≥50%, ECOG 0–1, measurable disease, and no actionable driver alterations or prior systemic therapy for advanced disease. Participants receive pumitamig/BNT327, an investigational bispecific antibody targeting PD-L1 and VEGF-A, versus standard pembrolizumab monotherapy.

ClinicalTrials.gov ID: NCT07361510

A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Randomized open-label trial for adults with previously untreated metastatic pancreatic ductal adenocarcinoma, ECOG 0–1, measurable disease, and adequate organ function. Patients receive atebimetinib, an investigational oral MEK1/2 inhibitor targeting MAPK signaling, plus modified gemcitabine/nab-paclitaxel versus standard gemcitabine/nab-paclitaxel.

ClinicalTrials.gov ID: NCT07562152

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling treatment-naive adults with recently diagnosed metastatic pancreatic adenocarcinoma, ECOG 0–1, measurable disease, and documented RAS mutation status. Patients are randomized to oral daraxonrasib, an investigational RAS(ON) inhibitor targeting active GTP-bound RAS signaling, either alone or with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel alone.

ClinicalTrials.gov ID: NCT07491445

A Phase 2 Study of BT5528 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic pancreatic ductal adenocarcinoma, ECOG 0–1, measurable disease, and radiographic progression after exactly one prior systemic therapy receive nuzefatide pevedotin (BT5528) monotherapy. BT5528 is an EphA2-targeting bicyclic peptide–drug conjugate linked to MMAE, given every 2 weeks, with primary assessment of RECIST objective response.

ClinicalTrials.gov ID: NCT07450859

A Phase II Study of Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) in Patients With Progressing Metastatic Neuroendocrine Carcinomas (NECs)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with measurable, progressing metastatic high-grade neuroendocrine tumors (GI, pancreatic, or thoracic; Ki-67 >20%) or neuroendocrine carcinoma of any origin except small cell lung cancer, after at least one prior systemic therapy and with survivin-positive tumor tissue, receive open-label temozolomide plus SurVaxM. SurVaxM is an investigational survivin-targeted peptide vaccine given with Montanide and sargramostim to induce anti-survivin immune responses.

ClinicalTrials.gov ID: NCT06202066

A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Randomized open-label trial for men with progressive mCRPC, ECOG 0–1, after 1–2 androgen receptor pathway inhibitors and no prior taxane/cytotoxic chemotherapy for mCRPC. Patients receive BNT324/DB-1311, a B7-H3–targeted antibody-drug conjugate carrying a topoisomerase I inhibitor payload, versus standard docetaxel plus prednisone/prednisolone while continuing castration therapy.

ClinicalTrials.gov ID: NCT07365995